US FDA warning: Illegally marketed stem cell therapy made in substandard lab

By Flora Southey contact

- Last updated on GMT

(Image: Getty/patpitchaya)
(Image: Getty/patpitchaya)

Related tags: Stem cell, California, Fda

California-based StemGenex marketed its SVF drug without an approved biologics license application, according to the agency.

The US Food and Drug Administration (FDA) has issued StemGenex Biologic Laboratories a warning letter​ following an inspection of its San Diego facility.

StemGenex manufactures and sells stromal vascular fraction (SVF) drug product to treat a variety of diseases, including Alzheimer’s, Crohn’s, Parkinson’s, Type I and Type II diabetes, multiple sclerosis, and rheumatoid arthritis.

During the audit, FDA investigators observed “significant deviations” ​from current good manufacturing practice (cGMP) requirements in the manufacture of the firm’s SVF product, “including unvalidated manufacturing processes, an uncontrolled environment, lack of control over the components used in production, and the lack of sufficient and validated product testing.”

In addition, the agency has claimed StemGenex put patients at risk by illegally marketed the drug.

“Your SVF product is not the subject of an approved biologics license application nor is there an investigational new drug [application] in effect.

“Based on this information, we have determined that your actions have violated the Food, Drug and Cosmetic Act and the Public Health Service Act,” ​according to US regulator.

Gottlieb: Long-term viability of stem cell industry at risk

Yesterday, FDA commissioner Scott Gottlieb spoke out​ against ‘bad actors’ in the stem cell therapy space.

“The potential health benefits of regenerative medicine have spurred major progress in stem-cell biology over the past several decades. But we continue to see bad actors exploit the scientific promise of this field to mislead vulnerable patients into believing they’re being given safe, effective treatments; when instead these stem cell producers are leveraging the field’s hype to push unapproved, unproven, illegal, and potentially unsafe products,” ​said the commissioner.

According to Gottlieb, such practices are putting the industry’s long-term viability at risk.

“We’ll continue to take enforcement actions companies that … [promote] so-called ‘treatments’ that haven’t been proven safe or effective for any use,” ​he added.

StemGenex did not respond to a request for comment ahead of publication.

Related news

Related products

show more

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Featured eBook: Complex Protein Production

Featured eBook: Complex Protein Production

Catalent Pharma Solutions | 06-Mar-2018 | Technical / White Paper

Download the eBook written by Catalent experts to learn about innovative products and techniques for scale-up of complex biologics, get optimal cell culture...

Related suppliers

Follow us

Products

View more

Webinars